Le Lézard
Classified in: Health
Subjects: NPT, TRI

Brooks Rehabilitation participates in national stroke recovery trial using breakthrough technology

JACKSONVILLE, Fla., Sept. 22, 2022 /PRNewswire/ -- Brooks Rehabilitation's first participant in the national stroke recovery trial, EMAGINE, has just completed study participation. The randomized, double-blind study tests whether a non-invasive, wearable device that delivers an electromagnetic field to brain networks can reduce disability and improve recovery following moderate to severe ischemic stroke.

The study tests whether a non-invasive, wearable device can reduce disability following an ischemic stroke. 

Brooks is one of up to 20 research and medical institutions in the United States who have been selected to participate in this pivotal study, with Clinical Research Scientist and Director of Neuromuscular Research, Emily Fox, PT, DPT, PhD, leading the charge as Site Principal Investigator at Brooks.

The portable and user-friendly device, which received FDA Breakthrough Device Designation, is designed to accompany participants throughout their recovery journeys, beginning as early as acute hospitalization, and moving with them to the inpatient rehab facility and eventually home. The EMAGINE study allows participants to use the investigational therapy from their homes with the oversight of a trained caregiver. A study team member joins therapy sessions periodically using a remote computer platform.

"It has been such a pleasure collaborating with Dr. Fox and the research team to determine how the stroke program in the hospital can support the EMAGINE research study.  It is wonderful when research and operations can work together to ensure patients have access to opportunities like participating in this trial," said Amanda Osborne, PT, MBA, Vice President of Operations and Administrator for the Brooks Rehabilitation Hospital - University Campus.

The technology utilizes explanatory machine learning to extract biological features found in brainwaves. These features are then used to target networks in the brain via a low-intensity, frequency-tuned electromagnetic field therapy with the goal of facilitating neuro-recovery. The therapy is intended to be used in combination with the current standard of care in physical or occupational therapy. 

"Working with industry partners to conduct research offers an outstanding opportunity for Brooks patients," explains Dr. Fox, Site Principal Investigator. "I have been particularly excited about this clinical trial because of the potential advancements in post-stroke rehabilitation. The focus on innovative technology and rehabilitation that transitions from the hospital to the home allows us to support patients and caregivers throughout their recovery."

Stroke is a leading cause of disability in the US and around the world. Every year, one in four people will suffer from a stroke in the US, according to the Centers for Disease Control and Prevention, creating a significant burden on their families and friends, and society as a whole.

System Medical Chief Officer at Brooks, Trevor Paris, M.D., FAAPMR, is a great supporter of innovative solutions in rehabilitation.

"Brooks has a long history of providing rehabilitation to patients with stroke and is always looking for cutting-edge technologies that can enhance our patients' outcomes. Participation in the EMAGINE trial is another step in that quest to enable our patients to achieve their highest potential. We see participation in this national trial as a way to not only help our community of stroke survivors, but potentially improve the lives of stroke patients across the country," he said.

The study is funded by BrainQ, the technology company that developed the investigational device. 

"With their notable and innovative approach to stroke care and dedication to community outreach, Brooks is a true partner in furthering our mission to redesign what recovery looks for stroke victims," stated Yotam Drechsler, CEO of BrainQ. "We're honored to be working together."

The EMAGINE stroke recovery trial will enroll 150 randomized subjects nationwide 4-21 days following a stroke. Trial participants will undergo 45 sessions over a total of 9 weeks, 5 times a week. Each session will last for 60 minutes. 

Eligible participants will be identified through Brooks Rehabilitation, and recruitment is now open. For more information, visit the EMAGINE website

More about Brooks Rehabilitation

For more than 50 years, Brooks Rehabilitation, headquartered in Jacksonville, Fla., has been a comprehensive source for physical rehabilitation services. As a nonprofit organization, Brooks operates one of the nation's largest inpatient rehabilitation hospitals in the U.S. with 160 beds, a second 60-bed inpatient hospital that opened in April 2022, and a Center for Inpatient Rehabilitation in partnership with Halifax Health in Daytona Beach, Fla.

Brooks also has one of the region's largest home healthcare agencies, more than 40 outpatient therapy clinics, the Brooks Rehabilitation Medical Group, two skilled nursing facilities, assisted living and memory care. Brooks will treat more than 60,000 patients through its system of care each year. In addition, Brooks operates the Clinical Research Center, which specializes in research to advance the science of rehabilitation. Brooks also provides many low- or no-cost community programs and services to improve the quality of life for people living with physical disabilities.

For more information, visit BrooksRehab.org.

About BrainQ 

BrainQ, the EMAGINE Stroke Recovery Trial sponsor, is a US and Israel-based company pioneering a novel therapy for reducing disability and maximizing the recovery potential for stroke and other neurodisorder victims. Their investigational device received FDA Breakthrough Device Designation. Their mission is to restore independence for the millions of people suffering from disability worldwide with a home-based accessible solution.

Worldwide, the BrainQ technology is limited to investigational use only and is not approved or available for sale. BrainQ makes no guarantees regarding clinical trial outcomes or regulatory approval for its technology.

Media contacts

Brooks Rehabilitation:
Jill Matejcek 

Madeleine Truitt 

SOURCE Brooks Rehabilitation

These press releases may also interest you

at 18:30
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab?a novel, patient-tailored monoclonal antibody therapy?showed promising results both while taking the drug and up to 20 weeks after the therapy was...

at 18:26
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA, in coordination with the U.S. Department of Agriculture and the Centers for Disease Control and Prevention, collaborated...

at 17:43
Lumiera Health Inc. (the " Company " or "Lumiera"). Further to the Company's December 6, 2022 press release, the Company wishes to provide an update on its situation....

at 17:19
All-Stat Portable announced the strategic acquisition of Texas-based GHC Imaging, greatly extending All-Stat Portable's service area. All-Stat Portable reassured Texas clients and patients that they would continue to receive the same excellent care...

at 17:15
Denis Arsenault (the "Acquiror"), located at Rue Sonnhaldenstrasse, 1A, Hergiswil Switzerland, 6052, announced today that on December 7, 2022, he acquired 3,452,595 warrants (the "Warrants") of Jushi Holdings Inc. (the "Issuer") pursuant to a private...

at 17:13
Tantus Technologies, Inc. (Tantus), as part of the C&T Solutions Team, announced today a new task order award under the Centers for Medicare and Medicaid Services' (CMS) Measure and Instrument Development and Support (MIDS) Indefinite Delivery...

News published on 22 september 2022 at 15:49 and distributed by: